Lexeo Therapeutics: Behind The Rebound

Lexeo Therapeutics, Inc. surges after FDA trial alignment for LX2006 in Friedreich’s ataxia. Click for more on LXEO stock ...
BioProcess International

Matica and Calidi team to advance cancer therapy

Contract development and manufacturing organization (CDMO) Matica Biotechnology has partnered with Calidi Biotherapeutics to advance and manufacture CLD-401, a tumor-tropic oncolytic virus designed to ...
The Manila Times

Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease

Outcome of Regenerative Medicine Advanced Therapy (RMAT) meeting provides the potential for an accelerated regulatory pathway to approval of OPGx-LCA5First participant enrolled in run-in period for ...

Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance

Third quarter revenues up 6% driven by EXPAREL volume growth of 9% -- -- Several key milestones advance 5x30 path to growth ...

Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today ...